METHYLENETETRAHYDROFOLATE REDUCTASE C677T GENE POLYMORPHISM AND PROSTATE CANCER RISK

Samah Tellouche-bouhouhou; Djalila Chellat-rezgoune; Noureddine Abadi; Dalila Satta; Abderrezak Dahdouh

doi:10.22159/ajpcr.2018.v11i5.24390

Authors

Samah Tellouche-bouhouhou Department of Animal Biology, University of FrÃ¨res Mentouri Constantine 1, Faculty of Natural and Life Sciences, Laboratory of Molecular and Cellular Biology, 25000 Constantine, Algeria.
Djalila Chellat-rezgoune Department of Animal Biology, University of FrÃ¨res Mentouri Constantine 1, Faculty of Natural and Life Sciences, Laboratory of Molecular and Cellular Biology, 25000 Constantine, Algeria.
Noureddine Abadi Department of Medicine, University Salah Boubnider Constantine
Dalila Satta Department of Medicine, University Salah Boubnider Constantine
Abderrezak Dahdouh Department of Urology and Renal Transplantation, Hospital of Uro-Nephrology, Daksi, 25001 Constantine, Algeria.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i5.24390

Keywords:

Methylenetetrahydrofolate reductase C677T, Polymorphism, Prostate cancer, East of Algeria

Abstract

Objective: The single nucleotide polymorphism C677T of the methylenetetrahydrofolate reductase (MTHFR) gene encodes a thermolabile enzyme. This polymorphism was found to be implicated in cancer susceptibility. In this study, we analyzed the distribution of the MTHFR C677T polymorphism in two cohorts; patients and controls native of East of Algeria to explore the possible association between this polymorphism and prostate cancer susceptibility.

Methods: Our examination has been conducted in 98 cases and 98 healthy controls. Genotyping was realized by polymerase chain reaction-restriction fragment length polymorphism method.

Results: Compared with CC homozygous, the CT heterozygous was found to have a significantly increased risk of prostate cancer (p=0.04; odds ratio [OR]=2.01, 95% confidence interval [CI]: 1.02â€“3.95). However, no statistically significant difference was observed concerning the TT homozygous (p=0.74; OR=1.25, 95% CI: 0.51â€“3.04).

Conclusion: Our results indicate that the genotype CT is a risk factor for prostate cancer in East of Algeria.

Downloads

Download data is not yet available.

References

Sepehr S, Sepehri H, Khodagholi F, Delphi L, Dashtbozorgi S. Apple pectin (AP) induced apoptosis via nitric oxide (NO) in human prostate cancer cells DU145. Int J Pharm Pharm Sci 2015;7:281-5.

Purushothaman A, Kumar G, Gangadharan P, Roshni PR. A comparison of leuprolide acetate versus bilateral orchiectomy for patients with metastatic prostate cancer. Asian J Pharm Clin Res 2016;9:51-4.

Kaur P, Khatik GL. Identification of novel 5-styryl-1,2,4-oxadiazole/ triazole derivatives as the potential anti-androgens through molecular docking study. Int J Pharm Pharm Sci 2016;8:72-7.

Reljic A, Simundic AM, Topic E, Nikolac N, Justinic D, Stefanovic M, et al. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: The croatian case-control study. Clin Biochem 2007;40:981-5.

Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML, et al. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999;6:359-65.

Johansson M, Van Guelpen B, Hultdin J, Wiklund F, Adami HO, BÃ¤lter K, et al. The MTHFR 677Câ†’T polymorphism and risk of prostate cancer: Results from the CAPS study. Cancer Causes Control 2007;18:1169-74.

Van Guelpen BR, WirÃ©n SM, Bergh AR, Hallmans G, Stattin PE, Hultdin J. Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: A nested caseâ€“control study. Eur J Cancer Prev 2006;15:46-50.

Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.

Sherzay N, Chitakar E. Epigenetics: Effect of environmental factors on human genome. Int J Pharm Pharm Sci 2016;8:1-6.

Sonbolestan ES, Sazgar H, Zia-Jahromi N, Farsani FM. Investigation the association between MTHFR gene polymorphism and homocysteine in iranian pregnant women. Asian J Pharm Clin Res 2017;10:411-4.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.

Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS, Franco RF 5,10-methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1956-63.

Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer:A meta-analysis. Gastroenterology 2006;131:1271-83.

Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med 2001;138:164-76.

Fard-Esfahani P, Fard-Esfahani A, Saidi P, Fayaz S, Mohabati R, Majdi M, et al. An increased risk of differentiated thyroid carcinoma in iran with the 677Câ†’T homozygous polymorphism in the MTHFR gene. Cancer Epidemiol 2011;35:56-8.

Wang ZG, Cui W, Yang LF, Zhu YQ, Wei WH. Association of dietary intake of folate and MTHFR genotype with breast cancer risk. Genet Mol Res 2014;13:5446-51.

LÃ³pez-CortÃ©s A, Jaramillo-Koupermann G, MuÃ±oz MJ, Cabrera A, EcheverrÃa C, Rosales F, et al. Genetic polymorphisms in MTHFR (C677T, A1298C), MTR (A2756G) and MTRR (A66G) genes associated with pathological characteristics of prostate cancer in the ecuadorian population. Am J Med Sci 2013;346:447-54.

Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009. p. 243-8.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.

Marchal C, Redondo M, Reyes-Engel A, Perea-Milla E, Gaitan MJ, Machuca J, et al. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur J Surg Oncol 2008;34:805-10.

Abedinzadeh M, Zare-Shehneh M, Neamatzadeh H, Abedinzadeh M, Karami H. Association between MTHFR C677T polymorphism and risk of prostate cancer: Evidence from 22 studies with 10,832 cases and 11,993 controls. Asian Pac J Cancer Prev 2015;16:4525-30.

Cicek MS, Nock NL, Li L, Conti DV, Casey G, Witte JS, et al. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2004;13:1331-6.

Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: A population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2009;18:2528-39.

Zhang WB, Zhang JH, Pan ZQ, Yang QS, Liu B. The MTHFR C677T polymorphism and prostate cancer risk: New findings from a meta-analysis of 7306 cases and 8062 controls. Asian Pac J Cancer Prev 2012;13:2597-604.

Guo S, Jiang X, Chen X, Chen L, Li X, Jia Y, et al. The protective effect of methylenetetrahydrofolate reductase C677T polymorphism against prostate cancer risk: Evidence from 23 case-control studies. Gene 2015;565:90-5.

Cai D, Ning L, Pan C, Liu X, Bu R, Chen X, et al. Association of polymorphisms in folate metabolic genes and prostate cancer risk: A case-control study in a Chinese population. J Genet 2010;89:263-7.

Li XL, Xu JH. MTHFR polymorphism and the risk of prostate cancer: A meta-analysis of case-control studies. Prostate Cancer Prostatic Dis 2012;15:244-9.

Safarinejad MR, Shafiei N, Safarinejad S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: A case-control study. Prostate 2010;70:1645-57.

KÃ¼Ã§Ã¼khÃ¼seyin Ã–, Kurnaz Ã–, Akadam-Teker AB, Narter F, YÄ±lmaz- AydoÄŸan H, Ä°sbir T, et al. Effects of the MTHFR C677T polymorphism on prostate specific antigen and prostate cancer. Asian Pac J Cancer Prev 2011;12:2275-8.

Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Int J Oncol 2004;25:1465-71.

Heijmans BT, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG, Kromhout D, et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 2003;63:1249-53.

Sumathi R, Tamizharasi S, Sivakumar T. Formulation and evaluation of polymeric nanosuspension of naringenin. Int J App Pharm 2017;9:60-70.